Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyAcetic acid
Identification
- Name
- Acetic acid
- Accession Number
- DB03166 (EXPT00423, DB04184)
- Type
- Small Molecule
- Groups
- Approved
- Description
Acetic acid is a product of the oxidation of ethanol and of the destructive distillation of wood. It is used locally, occasionally internally, as a counterirritant and also as a reagent. (Stedman, 26th ed) Acetic acid otic (for the ear) is an antibiotic that treats infections caused by bacteria or fungus.
- Structure
Structure for Acetic acid (DB03166)
- Synonyms
- Acetic acid, glacial
- Aceticum acidum
- acide acétique
- ácido acético
- Essigsäure
- Ethanoat
- Ethanoate
- Ethanoic acid
- Ethoic acid
- Ethylic acid
- Glacial acetic acid
- HOAc
- Methanecarboxylic acid
- Vinegar
- External IDs
- E-260 / FEMA NO. 2006 / INS NO.260 / INS-260 / NSC-111201 / NSC-112209 / NSC-115870 / NSC-127175 / NSC-132953 / NSC-406306
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Unlock Additional DataAcetic Acid Solution 20.65 mg/1mL Auricular (otic) A S Medication Solutions 2010-01-22 Not applicable US 
Acetic Acid Solution 20.65 mg/1mL Auricular (otic) Lake Erie Medical DBA Quality Care Products LLC 2010-01-22 Not applicable US Acetic Acid Solution 20.65 mg/1mL Auricular (otic) Rebel Distributors 2010-01-22 Not applicable US Acetic Acid Solution 20.65 mg/1mL Auricular (otic) Preferred Pharmaceuticals Inc. 2018-08-06 Not applicable US Acetic Acid Irrigant 250 mg/100mL Irrigation Icu Medical Inc. 2019-11-25 Not applicable US Acetic Acid Irrigant 0.25 g/100mL Irrigation B. Braun Medical Inc. 1979-08-06 Not applicable US Acetic Acid Solution 20.65 mg/1mL Auricular (otic) Nucare Pharmaceuticals,inc. 2010-01-22 Not applicable US Acetic Acid Irrigant 250 mg/100mL Irrigation Baxter Healthcare Corporation 1982-02-19 Not applicable US Acetic Acid Irrigant 250 mg/100mL Irrigation Hospira, Inc. 1980-01-01 Not applicable US Acetic Acid Solution 0.02 mL/1mL Auricular (otic) Vintage Pharmaceuticals, LLC 2007-01-25 2007-01-25 US Additional Data Available- Application NumberApplication Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Unlock Additional DataAcetic Acid Solution 0.02 mg/1mL Auricular (otic) A-S Medication Solutions 2005-02-24 2017-05-31 US Acetic Acid Solution 20 mg/1mL Auricular (otic) Morton Grove Pharmaceuticals, Inc. 1996-07-26 Not applicable US Acetic Acid Solution 20 mg/1mL Auricular (otic) Rising Pharmaceuticals, Inc. 2018-03-14 Not applicable US Acetic Acid Solution / drops 2 mg/1mL Auricular (otic) Bauch & Lomb Incorporated 1994-02-25 2017-09-01 US Acetic Acid Solution 20 mg/1mL Auricular (otic) A-S Medication Solutions 1996-07-26 Not applicable US Acetic Acid Solution 20 mg/1mL Auricular (otic) Unit Dose Services 1996-07-26 Not applicable US Acetic Acid Solution 25 mg/1mL Auricular (otic) Nucare Pharmaceuticals,inc. 1996-07-26 Not applicable US Acetic Acid Solution 0.02 mg/1mL Auricular (otic) Qualitest 2005-02-24 2017-05-31 US Borofair Solution / drops 2 mg/1mL Auricular (otic) Major 1994-02-25 2018-07-06 US Additional Data Available- Application NumberApplication Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Acetasol HC Acetic acid (2.41 g/100mL) + Hydrocortisone (1.1 g/100mL) Solution Auricular (otic) Physicians Total Care, Inc. 1994-12-15 2012-06-30 US Acetasol HC Acetic acid (2.41 g/100mL) + Hydrocortisone (1.1 g/100mL) Solution Auricular (otic) Actavis Pharma Company 2002-09-10 Not applicable US Acid Concentrate (r04146) Acetic acid (8.846 g) + Calcium chloride (9.477 g) + Dextrose, unspecified form (60.8 g) + Magnesium chloride (3.744 g) + Sodium chloride (184 g) Liquid Hemodialysis Genpharm Ulc 1997-05-21 2004-07-30 Canada 
Acid Concentrate (r04938) Acetic acid (8.846 g) + Calcium chloride (9.476 g) + Dextrose, unspecified form (60.77 g) + Magnesium chloride (3.744 g) + Potassium chloride (5.491 g) + Sodium chloride (172.2 g) Liquid Hemodialysis Genpharm Ulc 1987-12-31 2001-08-03 Canada Acid Concentrate (r04968) Acetic acid (8.846 g) + Calcium chloride (3.384 g) + Magnesium chloride (3.744 g) + Potassium chloride (5.491 g) + Sodium chloride (180.8 g) Liquid Hemodialysis Genpharm Ulc 1988-12-31 2004-07-30 Canada Acid Concentrate (r04969) Acetic acid (8.846 g) + Calcium chloride (3.384 g) + Magnesium chloride (3.744 g) + Potassium chloride (2.746 g) + Sodium chloride (180.8 g) Liquid Hemodialysis Genpharm Ulc 1988-12-31 2004-07-30 Canada Acid Concentrate (r04974) Acetic acid (8.846 g) + Calcium chloride (6.769 g) + Magnesium chloride (3.744 g) + Potassium chloride (8.237 g) + Sodium chloride (172.2 g) Liquid Hemodialysis Genpharm Ulc 1988-12-31 2004-07-30 Canada Acid Concentrate (r04975) Acetic acid (8.846 g) + Calcium chloride (6.769 g) + Magnesium chloride (3.744 g) + Potassium chloride (2.746 g) + Sodium chloride (172.2 g) Liquid Hemodialysis Genpharm Ulc 1988-12-31 2004-07-30 Canada Acid Concentrate (r04976) Acetic acid (8.846 g) + Calcium chloride (6.769 g) + Magnesium chloride (3.744 g) + Potassium chloride (5.491 g) + Sodium chloride (172.2 g) Liquid Hemodialysis Genpharm Ulc 1988-12-31 2004-07-30 Canada Acid Concentrate (r04981) Acetic acid (8.846 g) + Calcium chloride (8.122 g) + Dextrose, unspecified form (40.51 g) + Magnesium chloride (3.744 g) + Potassium chloride (2.746 g) + Sodium chloride (180.8 g) Liquid Hemodialysis Genpharm Ulc 1989-12-31 2004-07-30 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Fem pH Acetic acid (0.009 g/1g) + Oxyquinoline sulfate (0.00025 g/1g) Jelly Vaginal Pharmics, Inc. 1999-07-15 Not applicable US Otic Edge Acetic acid (100 ug/1mL) + Antipyrine (54 mg/1mL) + Benzocaine (14 mg/1mL) Solution Auricular (otic) River's Edge Pharmaceuticals, LLC 2008-09-01 2012-09-30 US Relegard Acetic acid (0.9 mg/1mL) + Oxyquinoline (0.025 mg/1mL) Gel Topical Blansett Pharmacal Co 2017-03-20 Not applicable US Treagan Otic Acetic acid (0.1 mg/1mL) + Antipyrine (54 mg/1mL) + Benzocaine (14 mg/1mL) Solution Topical Trigen Laboratories, Inc. 2009-09-01 2010-11-30 US - International/Other Brands
- Acetasol / Orlex / Volsol
- Categories
- Acetates
- Acids, Acyclic
- Anti-Bacterial Agents
- Anti-Infective Agents
- Compounds used in a research, industrial, or household setting
- Fatty Acids
- Fatty Acids, Volatile
- Genito Urinary System and Sex Hormones
- Gynecological Antiinfectives and Antiseptics
- Indicators and Reagents
- Laboratory Chemicals
- Lipids
- Organic Acids
- Otologicals
- Sensory Organs
- UNII
- Q40Q9N063P
- CAS number
- 64-19-7
- Weight
- Average: 60.052
Monoisotopic: 60.021129372 - Chemical Formula
- C2H4O2
- InChI Key
- QTBSBXVTEAMEQO-UHFFFAOYSA-N
- InChI
- InChI=1S/C2H4O2/c1-2(3)4/h1H3,(H,3,4)
- IUPAC Name
- acetic acid
- SMILES
- CC(O)=O
Pharmacology
- Indication
Used to treat infections in the ear canal.
- Associated Conditions
- Associated Therapies
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Bacteria
- Pathways
Pathway Category Aspartate Metabolism Metabolic Canavan Disease Disease Hypoacetylaspartia Disease Amino Sugar Metabolism Metabolic Ethanol Degradation Metabolic G(M2)-Gangliosidosis: Variant B, Tay-Sachs Disease Disease Pyruvate Kinase Deficiency Disease Heroin Metabolism Pathway Drug metabolism Pyruvate Metabolism Metabolic Leigh Syndrome Disease Pyruvate Dehydrogenase Complex Deficiency Disease Sialuria or French Type Sialuria Disease Sialuria or French Type Sialuria Disease Salla Disease/Infantile Sialic Acid Storage Disease Disease Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency) Disease Tay-Sachs Disease Disease Heroin Action Pathway Drug action Disulfiram Action Pathway Drug action Fatty Acid Biosynthesis Metabolic Primary Hyperoxaluria II, PH2 Disease - Pharmacogenomic Effects/ADRs
- Not Available
Unlock Additional Data
Additional Data Available
Adverse Effects
Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.
Learn more Additional Data Available
Contraindications
Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.
Learn more Additional Data Available
Blackbox Warnings
Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.
Learn moreInteractions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional Data(R)-warfarin The risk or severity of bleeding can be increased when Acetic acid is combined with (R)-warfarin. (S)-Warfarin The risk or severity of bleeding can be increased when Acetic acid is combined with (S)-Warfarin. 4-hydroxycoumarin The risk or severity of bleeding can be increased when Acetic acid is combined with 4-hydroxycoumarin. Acenocoumarol The risk or severity of bleeding can be increased when Acetic acid is combined with Acenocoumarol. BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Acetic acid. Clorindione The risk or severity of bleeding can be increased when Acetic acid is combined with Clorindione. Coumarin The risk or severity of bleeding can be increased when Acetic acid is combined with Coumarin. Dicoumarol The risk or severity of bleeding can be increased when Acetic acid is combined with Dicoumarol. Diphenadione The risk or severity of bleeding can be increased when Acetic acid is combined with Diphenadione. Ethyl biscoumacetate The risk or severity of bleeding can be increased when Acetic acid is combined with Ethyl biscoumacetate. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- No interactions found.
References
- Synthesis Reference
Earl M. Chamberlin, Warren K. Russ, Jr., George G. Hazen, "Process for preparing [1-oxo-2-cyclopentyl (or 2-isopropyl)-2-methyl-6,7-dichloro-5-indanyloxy] acetic acid." U.S. Patent US3950408, issued April, 1928.
US3950408- General References
- eMedicine [Link]
- External Links
- Human Metabolome Database
- HMDB0000042
- KEGG Drug
- D00010
- KEGG Compound
- C00033
- PubChem Compound
- 176
- PubChem Substance
- 46506148
- ChemSpider
- 171
- BindingDB
- 50074329
- RxNav
- 168
- ChEBI
- 15366
- ChEMBL
- CHEMBL539
- ZINC
- ZINC000005224164
- PharmGKB
- PA448021
- Guide to Pharmacology
- GtP Drug Page
- PDBe Ligand
- ACY
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Acetic_acid
- ATC Codes
- S02AA10 — Acetic acidG01AD02 — Acetic acid
- PDB Entries
- 1a3i / 1a7p / 1aa5 / 1at5 / 1bdw / 1be0 / 1bez / 1bkv / 1c0n / 1cag … show 857 more
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 0 Active Not Recruiting Diagnostic Cervical Cancers 1 1 Recruiting Diagnostic Gastric Intestinal Metaplasia 1 1 Recruiting Treatment Anatomic Stage IV Breast Cancer AJCC v8 / HER2 Positive Breast Carcinoma / Metastatic Breast Carcinoma / Prognostic Stage IV Breast Cancer AJCC v8 / Refractory Breast Carcinoma 1 2, 3 Terminated Diagnostic Esophagus, Barrett 1 Not Available Active Not Recruiting Prevention Cervical Cancers 1 Not Available Completed Screening Cervical Cancers 1 Not Available Enrolling by Invitation Basic Science Brain Function / Cerebral Blood Flow / Gut Microbiome / Metabolism 1 Not Available Recruiting Diagnostic Esophagus, Barrett 1 Not Available Unknown Status Diagnostic Colon Nos Polypectomy Tubular Adenoma / Colorectal Cancers / Serrated Adenomas 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- B. Braun Melsungen AG
- Bausch & Lomb Inc.
- Baxter International Inc.
- Dispensing Solutions
- Hi Tech Pharmacal Co. Inc.
- Hospira Inc.
- Major Pharmaceuticals
- Qualitest
- Taro Pharmaceuticals USA
- Vintage Pharmaceuticals Inc.
- Wockhardt Ltd.
- Dosage forms
Form Route Strength Irrigant Irrigation 0.25 g/100mL Irrigant Irrigation 250 mg/100mL Solution Auricular (otic) 0.02 mg/1mL Solution Auricular (otic) 0.02 mL/1mL Solution Auricular (otic) 20 mg/1mL Solution Auricular (otic) 20.65 mg/1mL Solution Auricular (otic) 25 mg/1mL Solution Hemodialysis Liquid Hemodialysis Solution / drops Auricular (otic) 2 mg/1mL Jelly Vaginal Gel Cutaneous; Infiltration Solution Auricular (otic) Gel Topical Solution Topical - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 16.6 °C PhysProp boiling point (°C) 117.9 °C PhysProp water solubility 1E+006 mg/L (at 25 °C) MERCK INDEX (1996) logP -0.17 HANSCH,C ET AL. (1995) logS 1.22 ADME Research, USCD pKa 4.76 (at 25 °C) SERJEANT,EP & DEMPSEY,B (1979) - Predicted Properties
Property Value Source Water Solubility 323.0 mg/mL ALOGPS logP -0.12 ALOGPS logP -0.22 ChemAxon logS 0.73 ALOGPS pKa (Strongest Acidic) 4.54 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 37.3 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 12.64 m3·mol-1 ChemAxon Polarizability 5.34 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9502 Blood Brain Barrier + 0.9742 Caco-2 permeable + 0.5968 P-glycoprotein substrate Non-substrate 0.8714 P-glycoprotein inhibitor I Non-inhibitor 0.99 P-glycoprotein inhibitor II Non-inhibitor 0.992 Renal organic cation transporter Non-inhibitor 0.9466 CYP450 2C9 substrate Non-substrate 0.7913 CYP450 2D6 substrate Non-substrate 0.9384 CYP450 3A4 substrate Non-substrate 0.7921 CYP450 1A2 substrate Non-inhibitor 0.8774 CYP450 2C9 inhibitor Non-inhibitor 0.9482 CYP450 2D6 inhibitor Non-inhibitor 0.9667 CYP450 2C19 inhibitor Non-inhibitor 0.9786 CYP450 3A4 inhibitor Non-inhibitor 0.9854 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9818 Ames test Non AMES toxic 0.9635 Carcinogenicity Carcinogens 0.6222 Biodegradation Ready biodegradable 0.9758 Rat acute toxicity 1.6315 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9666 hERG inhibition (predictor II) Non-inhibitor 0.9889
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as carboxylic acids. These are compounds containing a carboxylic acid group with the formula -C(=O)OH.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Carboxylic acids
- Direct Parent
- Carboxylic acids
- Alternative Parents
- Monocarboxylic acids and derivatives / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Monocarboxylic acid or derivatives / Carboxylic acid / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organooxygen compound / Carbonyl group / Aliphatic acyclic compound
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- monocarboxylic acid (CHEBI:15366) / Straight chain fatty acids, Saturated fatty acids (C00033) / Straight chain fatty acids (LMFA01010002)
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
- Gene Name
- SLCO2B1
- Uniprot ID
- O94956
- Uniprot Name
- Solute carrier organic anion transporter family member 2B1
- Molecular Weight
- 76709.98 Da
References
- Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 2003 Aug;306(2):703-8. Epub 2003 Apr 30. [PubMed:12724351]
- Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45. Epub 2003 Nov 10. [PubMed:14610227]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Symporter activity
- Specific Function
- Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucin...
- Gene Name
- SLC16A1
- Uniprot ID
- P53985
- Uniprot Name
- Monocarboxylate transporter 1
- Molecular Weight
- 53943.685 Da
References
- Tamai I, Sai Y, Ono A, Kido Y, Yabuuchi H, Takanaga H, Satoh E, Ogihara T, Amano O, Izeki S, Tsuji A: Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1. J Pharm Pharmacol. 1999 Oct;51(10):1113-21. [PubMed:10579682]
Drug created on June 13, 2005 07:24 / Updated on May 24, 2020 19:37
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates